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Objective: To study the toxicity and activity of two new amphotericin B formulations: poly(ε-caprolactone)
nanospheres coated with poloxamer 188 (AmB-NP) and mixed micelles with the same surfactant (AmB-MM).
Materials and methods: The toxicity of these formulations was evaluated in erythrocytes, J774.2 macro-
phages and LLCPK1 renal cells, as well as in mice. Activity was determined in clinical isolates and in neutro-
penic mice. Mice were made neutropenic with 5-fluorouracil, infected with Candida albicans and treated
with the antifungal formulations for three consecutive days. AmB association in cells and accumulation in
kidneys and liver of animals was quantified by HPLC.
Results: Both formulations decreased between 8- and 10-fold the MIC of the polyene against clinical isolates
of C. albicans. However, their activity was lower than or equal to that of AmB-deoxycholate when it was
assessed against C. albicans-infected macrophages. When given as a single intravenous dose in mice,
AmB-MM and AmB-NP had an LD50 of 9.8 and 18.6 mg/kg, respectively, compared with 4 mg/kg for AmB-
deoxycholate. Comparison of residual infection burdens in the liver and kidneys showed that AmB-deoxy-
cholate (0.5 mg/kg) was more effective and faster in eradicating yeast cells than polymeric formulations.
This fact can be related to a lower AmB accumulation inside macrophages and in liver and kidneys (about 1.5
mg drug/g tissue) of mice, compared with those detected for AmB-deoxycholate (4 mg drug/g). Overall, the
efficacy of these formulations at 2 mg/kg was equal to that of AmB-deoxycholate at 0.5 mg/kg.
Conclusions: AmB-MM and AmB-NP decreased the in vivo antifungal activity of AmB, and higher concentra-
tions were therefore necessary to obtain a similar therapeutic effect. However, these higher concentrations
were achievable owing to the reduced toxicity of these formulations.
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Introduction
Infections due to fungi of the genera Candida and Aspergillus have
become major nosocomial causes of morbidity and mortality in
immunocompromised individuals. Their incidence has increased
during the last three decades in parallel with the number of such
patients and it is now a commonplace complication.1,2 More recently,
there has been a substantial increase in the frequency of candidaemia
caused by species other than Candida albicans.3
Systemic candidiasis is associated with a high mortality rate
and prolonged hospitalization.4 The treatment options are extremely
limited. Rapid treatment with amphotericin B (AmB) or fluconazole
is required to reduce the mortality observed in these patients.5 AmB
is a very potent antifungal agent, but it has multiple severe toxic
effects and about 36% rate of failure in the treatment of immuno-
compromised hosts.6 Thus, several lipid formulations (AmBisome,
Amphocil, Abelcet) have been developed and commercialized.7,8
Although they have been proven to reduce AmB toxicity, their toxic
effects and pharmacokinetic properties all differ and their use has
been limited by their expense. Moreover, it has been recognized that
the reduction in AmB toxicity was associated with a substantial
reduction in AmB activity.9–13 Various in vivo studies have demon-
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strated that higher doses of AmBisome (3 mg/kg) are often needed for
a treatment to be as effective as 0.6 mg/kg of AmB-deoxycholate. It is
difficult to understand the mechanism by which these lipid formula-
tions modify the therapeutic index of AmB14,15 as far as it implies
multiple and different factors for each one. However, for all of them,
it seems to be closely related to the strength of association between
the drug and lipid compounds of the formulation.8,16 Moreover, the
drug toxicity depends on its aggregation state.17,18 Aggregates are the
forms responsible for drug toxicity but monomers are sufficient for
the activity. The slow release of the drug from lipid formulations
ensures that the drug remains as a monomer and is unable to form the
aggregates responsible for drug toxicity and increased activity.19
Other factors could also play a role.16
Obviously, the reduction in activity is a problem for treating
severe fungal infections because high doses and rapid action are
required in order to improve the survival rate. Thus, we do not yet
have an ideal antifungal agent.
In previous work, we developed and characterized non-lipid formu-
lations for AmB.20–23 In spite of the weak association between the
drug and the polymers, they decreased the acute toxicity of AmB in a
mouse model.20 Since the decrease in antifungal activity of AmB
lipid formulations has been attributed to the stability of association
between the drug and lipid components of the carriers,10,13 in this
study we evaluated the activity of these new polymeric formulations
in vitro and in vivo in a mouse model of candidiasis. The toxicity of
the formulations was also studied against mammalian cells and in
mice after a single bolus administration to obtain information on the
mechanism of action of AmB associated with these polymeric formu-
lations.
Materials and methods
Chemicals
Squibb (Madrid, Spain) kindly supplied amphotericin B. Poly(ε-caprol-
actone) (mol. wt 42500), was supplied by Sigma (Madrid, Spain) and
poloxamer 188 (Pluronic F68) by Comercial Química Massó (Barcelona,
Spain). All other chemicals were reagent grade. Culture media were
obtained from Gibco (France).
Preparation of AmB dispersions
AmB nanoparticles (AmB-NP) and mixed-micelles (AmB-MM) were
prepared by a solvent displacement method as previously described.20–22
Briefly, 125 mg poly(ε-caprolactone) and 10 mg amphotericin B were
dissolved in 30 mL of a mixture of organic solvents (methanol/acetone;
1:2 v/v) and acidified with 0.1 M HCl. This organic phase was heated at
50°C for 10 min and then poured into 40 mL of distilled water containing
125 mg poloxamer 188, under moderate magnetic stirring. The organic
solvents were eliminated by evaporation under vacuum and the resulting
nanoparticles (AmB-NP) concentrated to 10 mL.
Amphotericin B-mixed micelles (AmB-MM) were prepared as
described above, in the absence of poly(ε-caprolactone).
An aqueous dispersion of AmB used as a control was prepared by
solubilization of AmB in DMSO at a concentration of 10 mg/mL fol-
lowed by dispersion of this organic stock solution in water to yield an
initial concentration of 1 mg/mL (AmB).
Physicochemical characterization
Particle size analysis: The mean particle size of free dispersed AmB,
AmB-MM and AmB-NP was determined by photon correlation spectro-
scopy (PCS) on a Zetasizer 4 instrument (Malvern Instruments,
UK).
Stability of association upon dilution: CD spectroscopy: The aggrega-
tion state of the drug in AmB, AmB-MM and AmB-NP was analysed by
UV–visible (Cary 219 Varian spectrophotometer) and CD (Jobin-Yvon
V dichrograph) spectroscopy after dilution with distilled water to obtain
a final drug concentration of 50, 10, 5, 1 and 0.5 µg/mL (path lengths of
cuvettes 0.2, 1, 2, 5 and 10 cm, respectively). CD measurements were
expressed in ∆ε, the differential molar dichroic absorption coefficient
(M–1 cm–1), the amplitude of dichroic doublet characteristic of AmB self-
association, and λ (ελ – εr = 0), the wavelength of the centre of the dichroic
doublet.
In vitro studies: toxicity of AmB formulations in human red 
blood cells (RBC)
Isolation of human erythrocytes: Human venous blood collected in tubes
containing EDTA was centrifuged at 1500g for 10 min, and plasma and
buffy coat were removed. Erythrocytes were then washed three times
with phosphate-buffered saline (PBS; pH 7.4, 0.15 M), and finally,
recovered in the same buffer at a haematocrit of 40%.
Measurement of antibiotic-induced haemoglobin and potassium (K+)
release from RBC: AmB dispersions were diluted to different concentra-
tions (0.1–100 µM) with PBS and incubated for 5 min at 37°C. Freshly
prepared erythrocytes were then added to a final haematocrit of 2%
(approximately 2 × 108 cells per mL) and incubated at the same tem-
perature for 1 h. The cell pellet was lysed with distilled water. K+ was
measured using a Flame Photometer 410 (Prolabo, Paris, France) and
haemoglobin estimated from its absorption at 560 nm recorded with a
spectrophotometer. Control RBC (2 × 108 cells per mL) incubated with
PBS alone were used to estimate the total potassium and haemoglobin
content. The remaining K+ or haemoglobin was calculated as a percent-
age of the total content. Results are given as the mean of one experiment
representative of three experiments carried out with each concentration
in triplicate.
In vitro studies: toxicity against non-infected J774.2 
macrophages and LLCPK1 renal cells (MTT viability assay)
The macrophage cell line J774.2 and renal cell line LLCPK1 were grown
in monolayers in a humidified atmosphere containing 5% CO2 at 37°C in
250 mL flasks containing Dulbecco’s modified Eagle’s Medium (DMEM,
Gibco) or Medium 199, respectively containing 4 mM L-alanine-L-
glutamine (Glutamax) supplemented with 10% fetal bovine serum (FBS),
penicillin (100 IU/mL) and streptomycin (100 µg/mL). The fetal bovine
serum, penicillin and streptomycin were purchased from Gibco-BRL.
For the experiments, cells in the pre-confluence phase were harvested
with trypsin and plated at 4 × 104 cells per well in 96-well microplates.
After adherence for 2 h at 37°C, the medium was replaced with different
concentrations of AmB and AmB formulations. Then, the cell viability
was evaluated after an 18 h incubation, by the colorimetric assay with
MTT, as follows. After washing the cells, 200 µL of a 0.5 mg/mL MTT
solution in DMEM medium was added to each well and incubated at
37°C for 4 h. The supernatants were removed and 200 µL extraction solu-
tion was added in order to solubilize the formazan salt. After 30 min at
room temperature under shaking, the absorbance of each well was meas-
ured at 550 nm.
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In vitro studies: association of AmB and AmB formulations by 
J774.2 and LLC-PK1 cells
Cells were plated as above and incubated in the presence of various AmB
concentrations (0–100 µM) for 18 h at 37°C to evaluate the total asso-
ciation of AmB with cells or at 4°C to evaluate the adsorbed fraction.
After incubation, the cells were rapidly cooled and washed three times
with phosphate buffer pH 7.4 to remove unbound AmB. Cells were lysed
with 50 µL Triton X-100 1% for 20 min at 37°C. The amount of AmB
was determined by an HPLC method previously reported.24 Briefly, the
analytical separation was carried out on a reversed-phase, 250 × 4 mm
end-capped column packed with 5 µm C8 silica particles (Lichrospher 60
Select B, Merck, Darmstadt, Germany). The chromatographic system
was a Hewlett-Packard HPLC (Waldbronn, Germany) equipped with a
HP 1100 quaternary pump, a HP 1100 autosampler and a HP 1100 diode
array detector set at 408 nm. The mobile phase consisted of acetonitrile
(40% by vol.), water (14.5%), and a buffer solution (45.5%) of 0.05 M
ammonium acetate, 0.02 M triethylamine and 4% acetic acid (pH 3). The
flow rate was 0.6 mL/min and the injection volume 100 µL. The limit of
quantification of amphotericin B in biological samples was 1 ng/mL and
the method was linear from 1 to 25000 ng/mL. The intra- and interassay
coefficients of variation were 2.6 and 4.4, respectively.24
In vitro activity against extracellular Candida albicans and 
against Candida albicans inside J774.2 macrophages
The test organisms were clinical isolates of Candida albicans (Clínica
Universitaria de Navarra, Dr Rubio) and ATCC number 44858 was used
as the control strain in all the experiments. These strains were maintained
on Sabouraud dextrose agar and passaged monthly. Before each experi-
ment, cells were grown on agar at 37°C for 24 h. A broth microdilution
technique in RPMI 1640 was chosen to test yeast susceptibility.25 The
inocula ranged from 104 to 105 cfu/mL and the range of concentrations
tested was 0.001–10 µg/mL for AmB and AmB polymeric formulations.
Studies were carried out in 96-well plates, at 37°C with agitation, and the
incubation time was 24 h. The drug concentration in the well that com-
pletely suppressed all fungal growth, as judged by visual inspection, was
recorded as the MIC. Each strain was tested at least three times.
Candida albicans ATCC 44858 was used for infecting macrophages.
For this purpose, C. albicans was opsonized by incubation with fresh
mouse serum for 1 h at 37°C under magnetic agitation. Macrophages
J774.2 were plated in 24-well plates at 4 × 105 cells/well. After 2 h adher-
ence, an inoculum of 3 × 105 cfu of opsonized C. albicans was then added
to the monolayer. After a 30 min uptake period, 2 × 105 yeast particles
were ingested and the non-ingested yeast was removed by washing the
monolayer three times with the DMEM medium. The macrophages were
reincubated for 24 h with the different AmB formulations. Percentage of
infection was calculated by lysing macrophages with Triton X-100
(0.2%) and subculturing in TSA plates, compared with an untreated con-
trol. The amount of drug uptake by the cells was also determined by the
HPLC method described above.
Acute toxicity of AmB formulations
Animal protocols were carried out in compliance with the regulations of
the ethical committee of the University of Navarra in line with the Euro-
pean legislation on animal experiments (86/609/EU).
Male Swiss mice, average weight 20–25 g (CIFA, Universidad de
Navarra, Spain), were housed under normal conditions with free access
to food and water. The animals were injected with 0.2 mL of the different
AmB formulations diluted in PBS in the lateral vein tail. In each experi-
ment, eight mice per dose were used, and three different experiments
were carried out with each AmB formulation. Mice were observed for
death after injection and daily thereafter for 7 days. The results were
pooled and the median LD50 at 7 days after treatment was calculated with
Grafit 3.0 software.
Activity of AmB formulations in experimental candidiasis: 
efficacy studies
For these experiments, male Swiss mice (20–25 g) were treated with
5-fluorouracil (5-FU) to induce neutropenia,26 then infected with C. albi-
cans and finally, treated with the different AmB formulations. Neutro-
penia was induced in animals with a single intravenous (iv) injection of
100 mg/kg 5-FU. This reduced the peripheral blood absolute neutrophil
count to <200 cells/mL, within 1 day after administration, and main-
tained it in that range for up to 10 days.26,27 One day after inducing neutro-
penia, mice were infected with the C. albicans ATCC 44858 strain by
injecting 0.2 mL of a dispersion of 106 cfu in the lateral tail vein. Finally,
24 h later, groups of 12 to 18 mice received iv injections of PBS buffer,
AmB-deoxycholate (0.5 mg/kg per day), AmB-MM and AmB-NP (0.5
and 2 mg/kg per day) via the tail vein for three consecutive days.
Organ culture and AmB accumulation
Cultures were carried out on liver and kidney samples taken 3 and 10 days
after the last treatment. The liver and kidneys of 3–5 mice were aseptic-
ally removed, weighed and homogenized in 10 mL of sterile saline. From
here, we made serial 10-fold dilutions. We plated 0.1 mL from each one
and from the undiluted sample on Sabouraud agar and they were incu-
bated at 37°C for 24 h. Therefore, the limit of detection was 100 cfu per
organ. The number of cfu per gram of tissue was calculated. Triplicate
determinations were made for each time point and organ. The AmB
accumulation was determined by HPLC in organs removed 24 h after the
last iv administration. Briefly, the liver and kidneys were removed,
weighed, homogenized in 1 mL of sterile saline and frozen at –40°C until
assayed. Weighed samples (approximately 0.5 g of the homogenate)
were placed in a glass tube along with 2 mL of methanol. The samples
were vortex mixed for 1 min and then centrifuged at 4500 rpm for 10 min.
A 200 µL sample of the supernatant was placed in an autoinjector vial,
and 100 µL injected into the HPLC system. The analytical conditions
were the same as previously described.24 Comparisons of the mean AmB
tissue concentrations were made between different formulations at two
doses by the non-parametric Kolmogorov–Smirnov test. A P value of
≤0.05 was considered to indicate a significant difference.
Results
Physicochemical characterization: stability of interaction of 
AmB with poloxamer 188 or poly(ε-caprolactone) in mixed 
micelles or nanospheres
The aggregation state of AmB in drug delivery systems and the stabil-
ity of the interaction between AmB and the carrier compounds have
been previously reported to be the main factor in determining the tox-
icity of the drug at the cellular level7,16–18 and also the exchange of
the drug with plasma proteins and hence its biodistribution.7,28–30
AmB forms aggregates in equilibrium with monomers at high AmB
concentrations, above its critical micellar concentration. The pro-
gressive dilution of an AmB suspension leads to a progressive   disso-
ciation of the aggregates into the monomeric form. The evolution of
the intensity of the dichroic doublet (% ∆ε/∆εmax at 50 µg/mL) as a
function of antibiotic concentration was used to evaluate the  stability
of association between AmB molecules in the aggregates (AmB),
between the drug and poloxamer (AmB-MM) and/or poly (ε-caprol-
actone) (AmB-NP). The profile of the curves intensity of doublet as a
function of antibiotic concentration (Figure 1) indicated a dissocia-
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tion of AmB that was concentration-dependent and a weak inter-
action between the drug and the polymer [poly(ε-caprolactone) or
poloxamer]. Besides a strong interaction with carrier components,
modifications in the AmB aggregation state were also reported to
decrease the toxicity of the drug31 and also seemed to play a pivotal
role in drug activity.32 In this sense, the association of AmB with
poloxamer or poly(ε-caprolactone) in mixed micelles (AmB-MM) or
nanospheres (AmB-NP) altered the conformation of the aggregates
as revealed by modifications in UV–visible21,22 and CD spectra
(Table 1). Briefly, the adsorption of AmB onto nanospheres (AmB-
NP) decreases AmB aggregation as reflected in the decrease in ∆ε
and the red-shift of the dichroic doublet. In contrast, the dispersion of
AmB with poloxamer in mixed micelles (AmB-MM) increased AmB
aggregation as indicated by the increase in ∆ε and the blue shift of the
dichroic doublet. Blue shift could be due to the presence of smaller
and more homogeneous aggregates. More details of the spectro-
scopic properties of these formulations have been described.21,22
The size of AmB-MM and AmB-NP was also analysed (Table 1)
because AmB self-aggregates have been associated with infusion-
related side effects and precipitation of the drug causing obstruction
of renal tubules.33 AmB dispersion with poloxamer 188 (AmB-MM)
or association with nanospheres (AmB-NP) decreased the size of
AmB aggregates (Table 1) and also prevented progressive aggrega-
tion34 and precipitation of free drug (data not shown).
In vitro toxicity: effects on RBC membranes
K+ and haemoglobin leakage from RBC has been extensively used as
an index of polyene toxicity.18 As estimated from the experimental
data, the AmB concentration required to trigger 50% K+ leakage was
about 1 µM for AmB, AmB-MM and AmB-NP. This value was
higher than the 0.3 µM previously reported by Gaboriau et al.31 The
association of AmB with polymers resulted in a large decrease in
their haemolytic activity efficiency. Whereas 50% haemolysis was
observed with 5 µM AmB, hardly any haemoglobin leakage was
observed with the different AmB formulations assayed over the
whole range of concentrations tested (0.1–100 µM).
Cytotoxicity and drug uptake by J774.2 macrophages and 
LLC-PK1 renal cells
Since nephrotoxicity is the most important dose-limiting side effect
of AmB therapy and macrophages act as a reservoir of the drug, a
comparison was made between the toxicity of AmB and AmB poly-
meric formulations in the murine macrophage J774.2 and the pig
kidney epithelial renal LLC-PK1 cell lines. Cell metabolism was
measured by reduction of dimethylthiazole diphenyltetrazolium bro-
mide (MTT) by mitochondria. The cytotoxicity induced by AmB and
AmB polymeric formulations as a function of drug concentration is
shown in Figure 2.
For J774.2 macrophages (Figure 2a), AmB showed a steep slope
and 10 µg/mL of drug induced 70% toxicity compared with the con-
trol. On the other hand, AmB-MM exhibited a low, dose-dependent
toxicity which reached only 20% at the maximum concentration tested
(100 µg/mL). However, AmB-NP toxicity was not concentration-
dependent and was found to be about 60% over the whole range of
drug concentrations tested (0.1–100 µg/mL). Unloaded nanoparticles
exhibited similar toxicity to AmB-NP, indicating that the mito-
chondrial toxicity of these formulations was probably due to the
poly(ε-caprolactone) polymer without any effect of AmB.
Compared with macrophages, the cytotoxicity of free AmB against
renal cells as revealed by MTT conversion was greatly decreased
(Figure 2b) and toxicity was completely absent when AmB was
associated with polymeric colloids (less than 20%) for both nano-
particle and mixed micelle formulations.
The differences in AmB toxicity between both types of cell line
and also the decreased toxicity of AmB polymeric formulations were
well correlated with the higher amount of drug taken up by macro-
phages (phagocytic cells) compared with renal cells (non-phagocytic
cells), as shown in Figure 3(a and b), respectively. For each cell line,
the association of AmB with polymers greatly decreased the uptake
of the drug, without notable differences between AmB-MM or
AmB-NP.
In vitro activity: extracellular Candida albicans
The MICs of AmB against seven isolates of C. albicans ranged from
0.63 to 1.25 mg/L. MICs of AmB-MM for the same isolates ranged
from 0.02 to 0.08 mg/L and of AmB-NP from 0.08 to 0.16 mg/L.
AmB-free poloxamer micelles and unloaded nanospheres were inac-
tive up to 1250 mg/L.
Figure 1. Evolution of the intensity of the dichroic doublet (% ∆ε/∆εmax) of AmB
(filled squares), AmB-MM (filled triangles) and AmB-NP (open circles) as a
function of the total AmB concentration (µg/mL) by dilution with distilled water
of stock preparations 1 mg/mL AmB. ∆εmax = ∆ε at 50 µg/mL AmB.
Table 1. Mean size (nm), centre λ (ελ – εr=0) (nm) and intensity (∆ε) 
of dichroic doublet of AmB in AmB, AmB-MM and AmB-NP
aMeasured at 50 µg/mL AmB.
Mean size ± S.D. (nm) 
(polydispersity index)
Dichroic doubleta
∆ε (M–1 cm–1)
λ (ελ – εr = 0) 
(nm)
AmB >1000 (1.0) 3970 335
AmB-MM 358 ± 62 5630 330
AmB-NP 282 ± 50 (0.10) 2340 333
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Activity against Candida albicans inside J774.2 macrophages
Figure 4 shows the antifungal activities of AmB formulations against
intracellular C. albicans after a 24 h incubation. Antifungal activity
was evaluated in terms of eradication of C. albicans from infected
macrophages determined by sub-culturing on Sabouraud plates.
It should be noted that no complete eradication of C. albicans was
observed up to a drug concentration of 2 mg/L. We did not study
higher AmB concentrations because of AmB toxicity towards the
host cells. The intracellular activity of free AmB (AmB) was slightly
higher than that of AmB-MM, and much higher than that of AmB-
NP. Thus, in spite of their increased direct antifungal activity, the
association of AmB with polymeric colloids only maintained or
even decreased the activity of the free drug against intracellular
C. albicans. Moreover, because a direct interaction of AmB with the
yeast inside the macrophage is necessary for drug activity,10–13 we
determined the effect of the carrier on AmB uptake by infected
macrophages. The uptake of AmB and AmB-polymeric formulations
was concentration-dependent and much higher for the free drug
(AmB). So, when cells were incubated with 1 and 2 mg/mL of AmB,
7 × 10–5 and 38 × 10–5 nmol of drug, respectively, were detected
inside a living cell; but this dropped to 1 × 10–5 nmol and 2–3 × 10–5
nmol (per living cell), when cells were incubated with 1 and 2 mg/L of
AmB-NP or AmB-MM. At 2 mg/L, it is also noteworthy that the
extent of AmB uptake was higher in infected than in non-infected
cells (Figure 3). When the macrophages were incubated with AmB
concentrations lower than 1 mg/L, the drug was undetectable inside
macrophages.
In vivo experiments: acute toxicity
The dose–toxicity relationship observed on day 7 in non-infected
Swiss mice receiving increasing doses of AmB-deoxycholate, AmB-
MM and AmB-NP is shown in Figure 5. The LD50 calculated from
these data was 4, 9.80 and 18.60 mg/kg for AmB-deoxycholate,
AmB-MM and AmB-NP, respectively. The maximum tolerated
dosage (MTD) was defined as the maximum dose that did not result
Figure 2. Mitochondrial toxicity (MTT test) of AmB, AmB-MM, AmB-NP and
unloaded nanoparticles against macrophages J774.2 (a) and renal cells LLC-PK1
(b) as a function of drug concentration, after 18 h incubation at 37°C (5% CO2) at
2 × 105 cells/mL in DMEM or Medium 199, respectively supplemented with 5%
FCS. Figure 3. Uptake by J774.2 cells (a) and LLC-PK1 cells (b) of the different AmB
formulations as a function of the antibiotic concentration, after 18 h incubation, at
37°C. Symbol explanation: AmB (filled squares), AmB-MM (filled triangles)
and AmB-NP (open circles).
M. S. Espuelas et al.
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in any deaths. For AmB, the MTD was 2 mg/kg; it was 5 mg/kg for
AmB-MM and 10 mg/kg for AmB-NP. When AmB was given at
doses greater than 4 mg/kg, all mice died immediately, probably by
pulmonary embolism. In contrast, AmB dispersions induced a delayed
mortality at the highest doses tested, suggesting other causes of death.
In vivo experiments: activity in experimental candidiasis
For studies of efficacy, groups of 12–15 neutropenic mice were
infected with 106 cfu of C. albicans per mouse and 24 h later they
were treated iv with AmB-deoxycholate at 0.5 mg/kg and AmB for-
mulations at 0.5 (Figure 6a) or 2 mg/kg (Figure 6b).
Untreated mice died between 1 and 3 days after infection. Admin-
istration of 1 mg/kg AmB-deoxycholate led to the immediate death of
the mice.
At 0.5 mg/kg, 100% of the mice treated with AmB-deoxycholate
survived, whereas for AmB-MM at this dose, no mice survived after
day 12 post-infection. At the end of experiment, only 33% of mice
treated with AmB-NP at 0.5 mg/kg survived. However, the efficacy
was dose-dependent and with 2 mg/kg of the formulations, 100% of
the infected mice survived longer than 20 days post-infection (Figure
6b).
Organ cultures
Organ burden for the liver and kidney was analysed. Candida accu-
mulates particularly in kidneys. Candida was below detectable levels
Figure 4. Antifungal activity (log10 cfu/mL) of the different AmB polymeric
formulations against C. albicans inside J774.2 macrophages after a 24 h incu-
bation. Symbol explanation: AmB (filled squares), AmB-MM (filled triangles)
and AmB-NP (open circles).
Figure 5. Amphotericin B toxicity after a single bolus administration in the tail
vein (0.2 mL) of male Swiss mice (20–25 g). The percentage survival at day 7 is
shown. Symbol explanation: AmB-deoxycholate (filled squares), AmB-MM
(filled triangles) and AmB-NP (open circles).
Figure 6. Survival of Candida-infected, neutropenic Swiss mice after treatment
with different AmB formulations: (a) AmB dose was 0.5 mg/kg; (b) AmB dose
was 2 mg/kg for AmB-MM and AmB-NP. Mice were made neutropenic by 5-FU
and inoculated with C. albicans as described in Materials and methods. Survival
was monitored over 25 days. Symbol explanation: Control (filled squares),
AmB-deoxycholate (crosses), AmB-MM (filled triangles) and AmB-NP (open
circles).
Polymeric carriers for amphotericin B
425
(<100 cfu per organ) from the liver and kidneys of surviving mice
treated with AmB-deoxycholate 0.5 mg/kg and AmB-NP 2 mg/kg at
day 3 after the last treatment (Table 3). However, the yeast could be
detected in the liver of those animals treated with AmB-MM at 0.5
and 2 mg/kg and AmB-NP at 0.5 mg/kg. At day 10, Candida was
undetectable from the liver and kidneys for all treatments, even for
AmB-NP 0.5 mg/kg for which the percentage survival was greatly
decreased.
Determination of AmB accumulation in organs
The amounts of AmB recovered in liver and kidneys were obtained
after administration of two doses of AmB 24 h after the last adminis-
tration of each of the treatments (Table 3). Following the 0.5 mg/kg
dose, AmB-MM and AmB-NP accumulation in liver and kidneys
was significantly lower than for AmB-deoxycholate, with no differ-
ences between the two polymeric formulations. When doses of 2 mg/kg
of AmB-polymeric formulations were administered, the levels of the
drug in kidneys were approximately 10–20% of those measured in
the liver. AmB concentrations in the kidneys increased in proportion
with the dose, which was not the case in the liver. The AmB concen-
trations found in the liver of mice treated with polymeric formula-
tions (AmB-MM or AmB-NP) at 2 mg/kg were higher than expected
based on the results at 0.5 mg/kg, suggesting the existence of an addi-
tional uptake mechanism for these formulations in this organ.
Discussion
Toxicity
The AmB polymeric formulations described here displayed a lower
in vivo toxicity than AmB-deoxycholate (Figure 5). This fact can be
associated with a reduction in AmB accumulation in kidneys and in
the liver of mice treated with AmB-polymeric formulations, com-
pared with the same dose of AmB-deoxycholate (0.5 mg/kg, Table
3). AmB nephrotoxicity (related to the level of the drug in the
kidneys14,35) and liver dysfunction are toxic effects mainly found
after chronic administration of sublethal doses.36 Furthermore, at
2 mg/kg, the observed increase in liver concentration exceeding dose
proportionality is consistent with a significant uptake of the drug by
macrophages.37–39 Moreover, an increase in the time of circulation
of AmB in blood could explain the low AmB amount found in the
liver, compared with AmB-deoxycholate (0.5 mg/kg), in spite of the
major contribution of this organ to AmB elimination.39 A decrease in
opsonization by plasma components and rapid MPS uptake have
been previously described for colloids composed of poloxamer.40–42
On the other hand, the low toxicity induced by our formulations at
the cellular level, as revealed by the lack of haemolysis in human
erythrocytes and by the results of MTT in macrophages (Figure 3a)
and renal cells (Figure 3b), were noticed and other factors implied in
the results of mice toxicity. In fact, polymeric AmB formulations
strongly decreased drug-induced haemolysis efficiency, but they
produced the same membrane permeability as free AmB measured
by K+ leakage. It is assumed that the permeabilizing effects (K+ leak-
age) are due to the ability of AmB to form transmembrane channels,43
whereas AmB must also induce oxidation of membrane lipid to cause
cell death (Hb leakage) at higher doses.44 K+ leakage from human red
blood cells has been previously related to the stability of association
between AmB and carrier compounds.16,45 All AmB dispersions
exhibited quite similar stability upon dilution (Figure 1) and, in fact,
no differences were found between them in their ability to affect
membrane permeability. The proportion of free drug was enough to
produce K+ release, the earliest toxic event at low drug concentra-
tion.19 On the other hand, conformational changes in the drug self-
aggregates (Table 1) induced by the association of the drug with
nanospheres or poloxamer 188 could help to prevent lipid oxida-
tion.30
Table 2. Organ burdens in liver and kidneys post-C. albicans infection and treatment
Data are expressed as means ± S.D.; limit of detection was >100 cfu/organ.
acfu below detectable levels.
cfu/g liver (×103) cfu/g kidney (×103)
Treatment Dose (mg/kg) 3 days 10 days 3 days 10 days
Control – 13.7 ± 0.5 no survivals 120 ± 2.3 no survivals
AmB-deoxycholate 0.5 0.5 ± 0.9 a 0.5 ± 0.5 0.3 ± 0.3
AmB-MM 0.5 4.3 ± 4.2 no survivals 14.9 ± 3.6 no survivals
2 9.0 ± 7.8 0.1 ± 0.1 6.9 ± 4.5 0.7 ± 0.8
AmB-NP 0.5 6.1 ± 8.7 <0.1a 7.0 ± 5.8 0.9 ± 1.5
2 a 1.4 ± 2.4 0.4 ± 0.4 2.2 ± 2.9
Table 3. AmB concentration in liver and kidneys 24 h after the last 
treatment
The drug was extracted and determined by HPLC as described in Materials and
methods. Data are expressed as means ± S.D.
aP < 0.05 versus AmB-deoxycholate treatment.
bP < 0.05 versus AmB-MM treatment.
µg AmB/g of tissue
Treatment Dose (mg/kg) liver kidneys
AmB-deoxycholate 0.5 9.0 ± 4.3 4.3 ± 0.3
AmB-MM 0.5 4.1 ± 1.2a 1.7 ± 0.1a
2 28.3 ± 9.1 5.1 ± 0.2
AmB-NP 0.5 2.2 ± 0.9a,b 1.8 ± 0.4a
2 28.4 ± 6.7b 5.9 ± 1.4b
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Also, a direct blockage of phagocytosis by poloxamer 18846 could
be the origin of the observed decreased AmB uptake by J774.2 macro-
phages and LLC-PK1 renal cells, avoiding toxic accumulation of the
antibiotic in mitochondrial vacuoles,47 and decreasing in vitro mito-
chondrial toxicity against these cells (Figure 2).
Activity
Owing to the reduced toxicity of these polymeric formulations, high
doses (2 mg/kg) of the AmB polymeric formulations presented here
were administrated in a model of systemic candidiasis in neutropenic
mice (Figure 5). These doses were required to achieve the same thera-
peutic effect as AmB-deoxycholate at 0.5 mg/kg (Figure 6) as also
described for AmB lipidic formulations.8,10,11
The activity of the formulations against candidiasis, was found to
depend on both (i) organ accumulation of AmB polymeric formula-
tions, which was not that of the organism in a disseminated infection,
and (ii) uptake of drug by infected cells in a way able to damage the
fungal cells.9–13
(a) Since the activity of a drug in a model of disseminated candid-
osis after iv administration of inoculum required high drug
concentrations in liver and especially in kidneys, the polymeric
formulations decreased the activity of AmB against C. albicans.
(b) Drugs associated with colloidal carriers are mainly targeted to
macrophages. Inside these cells, a direct interaction of AmB
with the yeast is necessary for intracellular drug activity. More-
over, macrophages can act as a reservoir. They release the drug
and then, it can attack microorganisms disseminated outside
cells. Extracellular C. albicans were eight-fold more sensitive to
AmB-MM and AmB-NP than to free drug. However, AmB-NP
and AmB-MM exhibited, respectively, lower or the same activ-
ity as the free drug against less accessible C. albicans inside
macrophages (Figure 4). Like AmBisome,9–13 the large decrease
in the uptake of AmB by cells found when the drug was asso-
ciated with polymeric colloids was not consistent with the fully
retained antifungal activity of some of our formulations (AmB-
MM). We suggest that the reduced uptake is compensated by a
synergic interaction found between AmB and poloxamer (not so
strongly associated as the drug with AmBisome compounds9,12)
at the fungal membrane,23 resulting in a level of activity against
intracellular C. albicans similar to that of AmB-deoxycholate. A
similar explanation has been put forward for the activity of
PEG-AmB-LIP.10,11
In summary, AmB polymeric formulations decreased the in vivo
antifungal activity of free drug and higher concentrations are neces-
sary to obtain a similar therapeutic effect. However, these doses
could be administered because the formulations also reduced the
toxicity of AmB. In addition, the formulations could be marketed at
a reasonable price. However, further experiments, especially related
to chronic toxicity, must be addressed to tackle the proposed AmB
formulations presented here as an intermediate alternative between
the high efficacy of AmB-deoxycholate and the low toxicity of
AmBisome.
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